PGP and cancer: Ixabepilone also shows low susceptibility to multiple resistance mechanisms because it is a poor substrate of P-gp, which is overexpressed in malignant neoplasms of solid tumors, as kidney, colon, liver, ovary, breast, and sarcomas [63].